Cytochrome P450 26A1 is a protein encoded by the CYP26A1 gene in humans. It is mapped on human chromosome 10q23-q24. CYP26A1 gene encodes cytochrome P450 enzyme, specifically involved in metabolic inactivation of retinoic acid (RA).

synthetic peptide corresponding to amino acids 481-495 of human CYP26A1

Yale Center for High Throughput Cell Biology IF-tested antibodies. Each antibody is tested by immunofluorescence against HUVEC cells using the Yale HTCB IF protocol. To learn more about us and Yale Center for High Throughput Cell Biology partnership, visit sigma.com/htcb-if. Anti-CYP26A1 (481-495) antibody produced in rabbit is suitable for western blotting at a dilution of 1:500-1:1,000.

CYP26A1 promotes cell survival properties and contributes to the carcinogenic process. Enhanced CYP26A1 expression causes a functional Vitamin A deficiency (VAD) state in skin that leads to neoplastic transformation of keratinocytes in an early phase during skin carcinogenesis. It has high ligand selectivity but accepts structurally related nuclear receptor agonists as inhibitors. CYP26A1 is the P450 isoform and can be targeted when designing retinoic acid (RA) metabolism blocking agents.

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.